IL6 and neoplasm: We then analyzed the trend of cancer-promoting factors involved in tumor/stroma crosstalk, such as FGF2 [8,15,20], and IL-6, this last systemically elevated in HNSCC patients [25], linked to resistance to therapy [26] and secreted from stromal fibroblasts in several cancer types [27].